ESR1 and breast carcinoma: Despite the fact that ER+ breast cancer exhibits a high initial response to hormonal therapy, drug resistance and cancer recurrence ultimately develop [4,5,6], especially in metastatic breast cancer patients who are treated with tamoxifen [7,8,9].